Marco Gottardis - 11 Jul 2024 Form 3 Insider Report for NKGen Biotech, Inc. (NKGN)

Role
Director
Signature
/s/ Pierre Gagnon as Attorney-in-Fact
Issuer symbol
NKGN
Transactions as of
11 Jul 2024
Net transactions value
$0
Form type
3
Filing time
18 Jul 2024, 17:52:26 UTC
Previous filing
18 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NKGN Stock Option (right to buy) 11 Jul 2024 Common Stock 300,000 $2.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 11, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning July 11, 2024, and ending July 11, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.

Remarks:

See Exhibit 24 - Power of Attorney